Back to Search Start Over

Voluntary and controlled weight loss can reduce symptoms and proton pump inhibitor use and dosage in patients with gastroesophageal reflux disease: a comparative study.

Authors :
Bortoli, N.
Guidi, G.
Martinucci, I.
Savarino, E.
Imam, H.
Bertani, L.
Russo, S.
Franchi, R.
Macchia, L.
Furnari, M.
Ceccarelli, L.
Savarino, V.
Marchi, S.
Source :
Diseases of the Esophagus; Feb2016, Vol. 29 Issue 2, p197-204, 8p
Publication Year :
2016

Abstract

A wide variety of pieces of evidence has suggested that obesity is associated with a significant increase in the risk for gastroesophageal reflux disease ( GERD) symptoms and its complications. The aim of this study was to evaluate the effect of weight loss on reflux symptoms in overweight/obese patients with proven GERD. We enrolled overweight/obese patients with typical GERD symptoms and erosive esophagitis. At baseline, patients underwent detailed reflux symptoms evaluation and anthropometric assessment, and were divided into two treatment groups: group A received proton pump inhibitor ( PPI) and a personalized hypocaloric diet and aerobic exercise; and group B received PPI and a 'standard of care diet'. The dietetic treatment was considered effective if at least 10% of weight loss was achieved within 6 months. All patients were evaluated in terms of anthropometric data, GERD symptoms, and PPI use. In group A, mean body mass index ( BMI) decreased from 30.3 ± 4.1 to 25.7 ± 3.1 ( P < 0.05), and mean weight decreased from 82.1 ± 16.9 kg to 69.9 ± 14.4 kg ( P < 0.05). In group B, there was no change in BMI and weight. Symptom perception decreased ( P < 0.05) in both groups during PPI therapy, but a higher improvement was recorded in group A. In group A, PPI therapy was completely discontinued in 27/50 of the patients, and halved in 16/50. Only 7/50 continued the same PPI dosage. In group B, 22/51 halved the therapy and 29/51 maintained full dosage of therapy, but none was able to discontinue PPI due to a symptom recurrence. Overall, weight loss of at least 10% is recommended in all patients with GERD in order to boost the effect of PPI on reflux symptom relief and to reduce chronic medication use. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
11208694
Volume :
29
Issue :
2
Database :
Complementary Index
Journal :
Diseases of the Esophagus
Publication Type :
Academic Journal
Accession number :
113417461
Full Text :
https://doi.org/10.1111/dote.12319